Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

Cancer Cell

Volumn 22, Issue 4, 2012, Pages 425-437

  Sturm, Dominik ^a   Witt, Hendrik ^a,b   Hovestadt, Volker ^a   Khuong Quang, Dong Anh ^c   Jones, David T W ^a   Konermann, Carolin ^a   Pfaff, Elke ^a   Tönjes, Martje ^a   Sill, Martin ^a   Bender, Sebastian ^a   Kool, Marcel ^a   Zapatka, Marc ^a   Becker, Natalia ^a   Zucknick, Manuela ^a   Hielscher, Thomas ^a   Liu, Xiao Yang ^c   Fontebasso, Adam M ^d   Ryzhova, Marina ^e   Albrecht, Steffen ^d   Jacob, Karine ^c   Wolter, Marietta ^f   Ebinger, Martin ^g   Schuhmann, Martin U ^g   van Meter, Timothy ^h   Frühwald, Michael C ⁱ   Hauch, Holger ^j   Pekrun, Arnulf ^k   Radlwimmer, Bernhard ^a   Niehues, Tim ^l   Von Komorowski, Gregor ^m   Dürken, Matthias ^m   Kulozik, Andreas E ^b   Madden, Jenny ⁿ   Donson, Andrew ⁿ   Foreman, Nicholas K ⁿ   Drissi, Rachid ^o   Fouladi, Maryam ^o   Scheurlen, Wolfram ^p   von Deimling, Andreas ^a,b   Monoranu, Camelia ^q   Roggendorf, Wolfgang ^q   Herold Mende, Christel ^b   Unterberg, Andreas ^b   Kramm, Christof M ^r   Felsberg, Jörg ^f   Hartmann, Christian ^s   Wiestler, Benedikt ^b   Wick, Wolfgang ^b   Milde, Till ^a,b   Witt, Olaf ^a,b   Lindroth, Anders M ^a   Schwartzentruber, Jeremy ^t   Faury, Damien ^c   Fleming, Adam ^c   Zakrzewska, Magdalena ^u   Liberski, Pawel P ^u   Zakrzewski, Krzysztof ^v   Hauser, Peter ^w   Garami, Miklos ^w   Klekner, Almos ^x   Bognar, Laszlo ^x   Morrissy, Sorana ^y   Cavalli, Florence ^y   Taylor, Michael D ^y   van Sluis, Peter ^z   Koster, Jan ^z   Versteeg, Rogier ^z   Volckmann, Richard ^z   Mikkelsen, Tom ^aa   Aldape, Kenneth ^ab   Reifenberger, Guido ^f   Collins, V Peter ^ac   Majewski, Jacek ^ad   Korshunov, Andrey ^a   Lichter, Peter ^a   Plass, Christoph ^a   Jabado, Nada ^c   Pfister, Stefan M ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁱ KLINIKUM AUGSBURG   (Germany)

^j Klinikum Heilbronn   (Germany)

^k KLINIKUM BREMEN MITTE   (Germany)

^l Children's Hospital   (Germany)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ Children's Hospital Colorado   (United States)

^o CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^p Cnopf'Sche Kinderklinik Nü Rnberg Children's Hospital   (Germany)

^q UNIVERSITY OF WÜRZBURG   (Germany)

^r MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t MCGILL UNIVERSITY   (Canada)

^u MEDICAL UNIVERSITY OF LODZ   (Poland)

^v POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^w SEMMELWEIS UNIVERSITY   (Hungary)

^x UNIVERSITY OF DEBRECEN   (Hungary)

^y HOSPITAL FOR SICK CHILDREN   (Canada)

^z UNIVERSITY OF AMSTERDAM   (Netherlands)

^aa HENRY FORD HOSPITAL   (United States)

^ab UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ac UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ad MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; GENE; GENE MUTATION; GLIOBLASTOMA; H3F3A GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSCRIPTOMICS;

EID: 84867606428     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.08.024     Document Type: Article

References (48)

1. Antonelli M., Buttarelli F.R., Arcella A., Nobusawa S., Donofrio V., Oghaki H., Giangaspero F. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J. Neurooncol. 2010, 99:209-215.
2. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
3. Bax D.A., Mackay A., Little S.E., Carvalho D., Viana-Pereira M., Tamber N., Grigoriadis A.E., Ashworth A., Reis R.M., Ellison D.W., et al. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin. Cancer Res. 2010, 16:3368-3377.
4. Brinkman A.B., Gu H., Bartels S.J., Zhang Y., Matarese F., Simmer F., Marks H., Bock C., Gnirke A., Meissner A., Stunnenberg H.G. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res. 2012, 22:1128-1138.
5. Broniscer A., Baker S.J., West A.N., Fraser M.M., Proko E., Kocak M., Dalton J., Zambetti G.P., Ellison D.W., Kun L.E., et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 2007, 25:682-689.
6. Capper D., Weissert S., Balss J., Habel A., Meyer J., Jäger D., Ackermann U., Tessmer C., Korshunov A., Zentgraf H., et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010, 20:245-254.
7. Chowdhury R., Yeoh K.K., Tian Y.M., Hillringhaus L., Bagg E.A., Rose N.R., Leung I.K., Li X.S., Woon E.C., Yang M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011, 12:463-469.
8. Christensen B.C., Smith A.A., Zheng S., Koestler D.C., Houseman E.A., Marsit C.J., Wiemels J.L., Nelson H.H., Karagas M.R., Wrensch M.R., et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 2011, 103:143-153.
9. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
10. De Carli E., Wang X., Puget S. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:2248.
11. Drané P., Ouararhni K., Depaux A., Shuaib M., Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010, 24:1253-1265.
12. Gibbons R.J., McDowell T.L., Raman S., O'Rourke D.M., Garrick D., Ayyub H., Higgs D.R. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet. 2000, 24:368-371.
13. Goldberg A.D., Banaszynski L.A., Noh K.M., Lewis P.W., Elsaesser S.J., Stadler S., Dewell S., Law M., Guo X., Li X., et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010, 140:678-691.
14. Gonzalo S., Jaco I., Fraga M.F., Chen T., Li E., Esteller M., Blasco M.A. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 2006, 8:416-424.
15. Heaphy C.M., de Wilde R.F., Jiao Y., Klein A.P., Edil B.H., Shi C., Bettegowda C., Rodriguez F.J., Eberhart C.G., Hebbar S., et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.
16. Hyland E.M., Molina H., Poorey K., Jie C., Xie Z., Dai J., Qian J., Bekiranov S., Auble D.T., Pandey A., Boeke J.D. An evolutionarily 'young' lysine residue in histone H3 attenuates transcriptional output in Saccharomyces cerevisiae. Genes Dev. 2011, 25:1306-1319.
17. Kaneda A., Kaminishi M., Yanagihara K., Sugimura T., Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 2002, 62:6645-6650.
18. Kang H.J., Kawasawa Y.I., Cheng F., Zhu Y., Xu X., Li M., Sousa A.M., Pletikos M., Meyer K.A., Sedmak G., et al. Spatio-temporal transcriptome of the human brain. Nature 2011, 478:483-489.
19. Khuong-Quang D.A., Buczkowicz P., Rakopoulos P., Liu X.Y., Fontebasso A.M., Bouffet E., Bartels U., Albrecht S., Schwartzentruber J., Letourneau L., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012, 124:439-447.
20. Ligon K.L., Alberta J.A., Kho A.T., Weiss J., Kwaan M.R., Nutt C.L., Louis D.N., Stiles C.D., Rowitch D.H. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 2004, 63:499-509.
21. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. WHO Classification of Tumors of the Central Nervous System 2007, IARC, Lyon.
22. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
23. McLendon R., Friedman A., Bigner D., Van Meir E.G., Brat D.J., Mastrogianakis M., Olson J.J., Mikkelsen T., Lehman N., Aldape K., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
24. Mehta S., Huillard E., Kesari S., Maire C.L., Golebiowski D., Harrington E.P., Alberta J.A., Kane M.F., Theisen M., Ligon K.L., et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011, 19:359-371.
25. Meissner A., Mikkelsen T.S., Gu H., Wernig M., Hanna J., Sivachenko A., Zhang X., Bernstein B.E., Nusbaum C., Jaffe D.B., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-770.
26. Monti S., Tamayo P., Mesirov J., Golub T. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 2003, 52:91-118.
27. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
28. Pang J.C., Li K.K., Lau K.M., Ng Y.L., Wong J., Chung N.Y., Li H.M., Chui Y.L., Lui V.W., Chen Z.P., et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 2010, 20:1021-1032.
29. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
30. Paugh B.S., Qu C., Jones C., Liu Z., Adamowicz-Brice M., Zhang J., Bax D.A., Coyle B., Barrow J., Hargrave D., et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 2010, 28:3061-3068.
31. Paugh B.S., Broniscer A., Qu C., Miller C.P., Zhang J., Tatevossian R.G., Olson J.M., Geyer J.R., Chi S.N., da Silva N.S., et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J. Clin. Oncol. 2011, 29:3999-4006.
32. Pfaff E., Remke M., Sturm D., Benner A., Witt H., Milde T., von Bueren A.O., Wittmann A., Schöttler A., Jorch N., et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J. Clin. Oncol. 2010, 28:5188-5196.
33. Pfister S., Remke M., Benner A., Mendrzyk F., Toedt G., Felsberg J., Wittmann A., Devens F., Gerber N.U., Joos S., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 2009, 27:1627-1636.
34. Pollack I.F., Hamilton R.L., Sobol R.W., Nikiforova M.N., Lyons-Weiler M.A., Laframboise W.A., Burger P.C., Brat D.J., Rosenblum M.K., Holmes E.J., et al. IDH1 mutations are common in malignant gliomas arising in adolescents: A report from the Children's Oncology Group. Childs Nerv. Syst. 2011, 27:87-94. Published online August 20, 2010. 10.1007/s00381-010-1264-1.
35. Puget S., Philippe C., Bax D.A., Job B., Varlet P., Junier M.P., Andreiuolo F., Carvalho D., Reis R., Guerrini-Rousseau L., et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE 2012, 7:e30313.
36. Qu H.Q., Jacob K., Fatet S., Ge B., Barnett D., Delattre O., Faury D., Montpetit A., Solomon L., Hauser P., et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-oncol. 2010, 12:153-163.
37. Schiffman J.D., Hodgson J.G., VandenBerg S.R., Flaherty P., Polley M.Y., Yu M., Fisher P.G., Rowitch D.H., Ford J.M., Berger M.S., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010, 70:512-519.
38. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T.W., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tönjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
39. Setty P., Hammes J., Rothämel T., Vladimirova V., Kramm C.M., Pietsch T., Waha A. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J. Mol. Diagn. 2010, 12:750-756.
40. Statham A.L., Robinson M.D., Song J.Z., Coolen M.W., Stirzaker C., Clark S.J. Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res. 2012, 22:1120-1127.
41. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
42. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
43. Wang Y., Yang J., Zheng H., Tomasek G.J., Zhang P., McKeever P.E., Lee E.Y., Zhu Y. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 2009, 15:514-526.
44. Wilkerson M.D., Hayes D.N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010, 26:1572-1573.
45. Wu G., Broniscer A., McEachron T.A., Lu C., Paugh B.S., Becksfort J., Qu C., Ding L., Huether R., Parker M., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 2012, 44:251-253. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
46. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
47. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
48. Zarghooni M., Bartels U., Lee E., Buczkowicz P., Morrison A., Huang A., Bouffet E., Hawkins C. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J. Clin. Oncol. 2010, 28:1337-1344.